Delving into the Latest Updates on BioQ Pharma, Inc. with Synapse

Overview

Pilot healthcare economics and observational study of the OneDose ReadyfusOR (a factory-filled infusion device delivering a continuous infusion of ropivacaine 2mg/ml for up to 48 hours), for the treatment of post-operative pain in patients who have undergone open intra-abdominal surgery (laparotomy)

Start Date15 Nov 2017

Sponsor / Collaborator

BioQ Pharma, Inc.

NCT02959476

/ CompletedPhase 3

A Double Blind, Multi-center, Randomized, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery

This study evaluates a Ropivacaine 0.2% Pre-Filled Dispenser in the treatment of post-surgical pain in patients undergoing Cesarean delivery. Half of the patients will receive Ropivicaine and half will receive placebo.

Start Date13 Mar 2017

Sponsor / Collaborator

BioQ Pharma, Inc.

[+1]

100 Clinical Results associated with BioQ Pharma, Inc.

Login to view more data

0 Patents (Medical) associated with BioQ Pharma, Inc.

Login to view more data

100 Deals associated with BioQ Pharma, Inc.

Login to view more data

100 Translational Medicine associated with BioQ Pharma, Inc.

Login to view more data